Research on engineered BCG has shown it can trigger trained immunity in tumor-associated macrophages and make glioblastoma more sensitive to radiotherapy in mice. This development is part of a broader area of study on trained immunity and its potential applications in cancer treatment. The role of trained immunity in health and disease is still being defined, with potential implications for various therapies, including cancer and autoimmune diseases.